Qualigen Therapeutics (QLGN) AI Stock Analysis

• Market Cap: $2.57M
• Dividend Yield: N/A
• Average Volume (3M): 77.77K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.48
• Revenue Growth: -100.00%
• EPS Growth: 69.07%
• Country: US
• Employees: 4
• Sector: Healthcare
• Sector Strength: 62
• Industry: Biotechnology
• EPS (TTM): -55.30
• Shares Outstanding: 736,431
• 10 Day Avg. Volume: 215,983
• 30 Day Avg. Volume: 77,765
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• Price to Cash Flow (P/CF): -0.30
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

Qualigen Therapeutics' overall stock score is low due to significant financial challenges, including declining revenue, substantial losses, and financial instability. The bearish technical analysis further dampens the outlook. However, recent corporate events like strategic investments and leadership changes provide a slight positive outlook on future potential improvements.

Qualigen Therapeutics Business Overview & Revenue Model

Company Description

Qualigen Therapeutics, Inc. (QLGN) is a biotechnology company that focuses on the development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases. The company operates in the healthcare sector, emphasizing innovative drug candidates and diagnostic technologies. Qualigen's core offerings include a pipeline of proprietary drug candidates aimed at addressing unmet medical needs in oncology and infectious diseases.

How the Company Makes Money

Qualigen Therapeutics generates revenue through multiple streams, primarily focusing on the development and commercialization of its therapeutic products. The company earns money by advancing its drug candidates through clinical trials and securing partnerships or licensing agreements with larger pharmaceutical companies. These collaborations often involve upfront payments, milestone payments based on the achievement of clinical and regulatory goals, and royalties on product sales. Additionally, Qualigen may derive revenue from its diagnostic technologies, which are used in clinical settings and research institutions. The company's financial performance is significantly influenced by its ability to successfully bring its drug candidates to market and establish strategic partnerships within the pharmaceutical industry.

Qualigen Therapeutics Financial Statement Overview

Summary

Qualigen Therapeutics faces significant financial challenges. The income statement reveals persistent revenue declines and substantial losses, while the balance sheet highlights financial instability with negative equity. Cash flow analysis indicates ongoing operational cash burn and reliance on financing. The company needs strategic financial management and operational improvements to stabilize its financial health.

Income Statement

Qualigen Therapeutics has experienced declining revenue recently, with the latest TTM period showing zero revenue. The company consistently reports significant net losses, evidenced by a negative net profit margin across recent periods. Gross profit margins are also negative, indicating cost management challenges. Historical revenue growth has been inconsistent, with recent declines. EBIT and EBITDA margins remain negative, highlighting operational inefficiencies and profitability issues.

Balance Sheet

The balance sheet shows significant financial distress, with negative stockholders' equity in the latest TTM period, indicating liabilities exceed assets. The company's debt-to-equity ratio is not meaningful due to negative equity, but high liabilities relative to assets suggest financial instability. Return on equity is negative, reflecting ongoing losses, and the equity ratio is concerning due to negative equity.

Cash Flow

Cash flow analysis shows negative operating cash flows, highlighting operational challenges. Free cash flow has been negative, indicating cash burn that may threaten sustainability without external financing. The company has relied on financing activities, as shown by cash inflows from financing, to support operations. Overall, cash flow metrics reflect a need for improved cash management and operational performance.

Breakdown
TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Mar 2020
Income Statement		Total Revenue
0.00	5.20M	4.98M	5.65M	4.31M	5.56M
	Gross Profit
-1.12M	-4.50K	680.80K	1.32M	-2.88M	1.58M
	EBIT
-6.70M	-11.30M	-17.94M	-22.66M	-11.30M	-1.50M
	EBITDA
-6.73M	-11.30M	-13.84M	-22.66M	-11.16M	-10.02M
	Net Income Common Stockholders
-7.87M	-13.42M	-21.03M	-17.90M	-20.42M	-1.79M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
14.09M	401.80K	7.03M	17.54M	23.98M	153.12K
	Total Assets
14.27M	2.03M	19.08M	22.84M	29.13M	3.72M
	Total Debt
0.00	1.30M	2.71M	1.68M	375.56K	2.22M
	Net Debt
-14.09M	897.41K	-4.33M	-15.86M	-23.60M	2.07M
	Total Liabilities
2.33M	4.14M	10.32M	6.27M	10.83M	5.65M
	Stockholders Equity
11.94M	-2.10M	7.24M	16.56M	18.29M	-1.93M
Cash Flow		Free Cash Flow
-9.73M	-10.30M	-13.57M	-14.87M	-9.97M	-137.15K
	Operating Cash Flow
-9.73M	-10.30M	-13.25M	-14.73M	-9.76M	57.33K
	Investing Cash Flow
-664.60K	4.22M	-183.76K	-141.36K	-160.56K	-194.48K
	Financing Cash Flow
4.83M	-550.00K	2.91M	8.43M	33.76M	165.14K

Qualigen Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 3.41
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For QLGN, the sentiment is Negative. The current price of 3.41 is above the 20-day moving average (MA) of 3.27, above the 50-day MA of 3.38, and below the 200-day MA of 6.70, indicating a neutral trend. The MACD of 0.06 indicates Negative momentum. The RSI at 54.49 is Neutral, neither overbought nor oversold. The STOCH value of 59.71 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for QLGN.

Qualigen Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	48 Neutral	$6.86B	1.11	-50.22%	2.47%	16.71%	1.53%
AVDL	46 Neutral	$725.69M	―	-60.44%	―	504.79%	74.24%
SLS	40 Underperform	$99.02M	―	-4147.88%	―	―	60.51%
CYCC	36 Underperform	$55.77M	―	-807.39%	―	-80.98%	62.27%
KPTI	36 Underperform	$29.79M	―	41.08%	―	-0.55%	49.85%
QLGN	31 Underperform	$2.57M	―	367.65%	―	-100.00%	69.07%

Qualigen Therapeutics Corporate Events

Qualigen Therapeutics Invests in NanoSynex’s Growth

On January 28, 2025, Qualigen Therapeutics announced its participation as the first investor in the 2025 bridge funding round for NanoSynex, which aims to raise up to $500,000. This investment supports the development of NanoSynex’s Antimicrobial Susceptibility Testing technology, which is expected to significantly enhance diagnostic speed and accuracy, potentially expanding the market to $4.7 billion by 2027. NanoSynex plans to enter the EU and US markets by 2027 and 2028, respectively, with a promising pipeline and four patents protecting its technology.

Qualigen Therapeutics Appoints Graydon Bensler to Board

Graydon Bensler has been appointed as an independent board member, bringing over seven years of financial consulting and management experience. A Chartered Financial Analyst, Bensler co-founded an Ed Tech company and held key roles in investor relations and investment banking. His expertise in capital markets and public company compliance is expected to benefit the board significantly.